Why The Hims & Hers Health Rally Has Room To Run

Hims & Hers reported strong Q1 FY25 results, with subscriber growth of 38% YoY to 2.4 million and revenue up 111% YoY to $586 million. Personalized treatments are driving growth, accounting for 58% of the subscriber base and contributing to a 50% YoY increase in monthly online revenue per subscriber to $84. These results support the company's FY27 targets of $3.4 billion in revenue and a $19.82 billion market cap.

Analysis

Hims & Hers Health, Inc. (HIMS) demonstrated significant operational momentum and financial acceleration in its Q1 FY25 results. The company reported a 111% year-over-year revenue increase to $586 million, substantially driven by a 38% YoY expansion of its subscriber base to 2.4 million. A key catalyst for this growth is the successful strategic pivot towards personalized treatments, which now account for 58% of all subscribers and were chosen by 70% of new users during the quarter. This shift is not only expanding the user base but also enhancing its value, as reflected in the 50% YoY surge in monthly online revenue per subscriber to $84. The effectiveness of this model is further evidenced by the dermatology segment, where subscriber growth hit 50% YoY, and the focus on personalized solutions led to a 20-point gain in customer retention. These strong quarterly results lend credibility to the company's ambitious FY27 targets, which project $3.4 billion in revenue and a potential 45% upside to its market capitalization.

Key Decisions for Investors

• Investors should recognize that the company's pivot to personalized medicine is a primary catalyst for both accelerated revenue growth and enhanced unit economics, as validated by the 50% increase in revenue per subscriber.
• Given the stock's recent 89.5% return, attention should be focused on the company's ability to execute on its ambitious FY27 revenue target of $3.4 billion, which is now the key benchmark for justifying further valuation expansion.
• The 20-point retention gain in dermatology linked to personalized regimens is a critical proof point; investors should monitor the adoption rate and retention metrics of personalized solutions across all verticals as a leading indicator of the strategy's long-term viability and competitive moat.